Jeremy Mills

Dr. Jeremy Mills

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2003 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DPDerek A. Pratt
Derek A. Pratt
JMJeremy Mills
Jeremy Mills
NPNed A. Porter
Ned A. Porter

18 November 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CLChang C. Liu
Chang C. Liu
AMAntha V. Mack
Antha V. Mack
MTMeng-Lin Tsao
Meng-Lin Tsao
JMJeremy Mills
Jeremy Mills
HLHyun Soo Lee
Hyun Soo Lee
VSVaughn V. Smider
Vaughn V. Smider
We have devised a phage display system in which an expanded genetic code is available for directed evolution. This system allows selection to yield proteins containing unnatural amino acids should such sequences functionally outperform ones containing only the 20 canonical amino acids. We have optimized this system for use with several unnatural amino acids and provide a demonstration of its utility through the selection of anti-gp120 antibodies. One such phage-displayed antibody, selected from a naïve germline scFv antibody library in which six residues in V H CDR3 were randomized, contains sulfotyrosine and binds gp120 more effectively than a similarly displayed known sulfated antibody isolated from human serum. These experiments suggest that an expanded “synthetic” genetic code can confer a selective advantage in the directed evolution of proteins with specific properties.

5 December 2012 in Journal of the American Chemical Society
Verified
Journal Article
Open access
SGSydney R. Gordon
Sydney R. Gordon
ESElizabeth J. Stanley
Elizabeth J. Stanley
SWSarah Wolf
Sarah Wolf
ATAngus Toland
Angus Toland
SWSean J. Wu
Sean J. Wu
JSJustin B. Siegel
Justin B. Siegel
The ability to rationally modify enzymes to perform novel chemical transformations is essential for the rapid production of next-generation protein therapeutics. Here we describe the use of chemical principles to identify a naturally occurring acid-active peptidase, and the subsequent use of computational protein design tools to reengineer its specificity toward immunogenic elements found in gluten that are the proposed cause of celiac disease. The engineered enzyme exhibits a kcat/KM of 568 M–1 s–1, representing a 116-fold greater proteolytic activity for a model gluten tetrapeptide than the native template enzyme, as well as an over 800-fold switch in substrate specificity toward immunogenic portions of gluten peptides. The computationally engineered enzyme is resistant to proteolysis by digestive proteases and degrades over 95% of an immunogenic peptide implicated in celiac disease in under an hour. Thus, through identification of a natural enzyme with the pre-existing qualities relevant to an ultimate goal and redefinition of its substrate specificity using computational modeling, we were able to generate an enzyme with potential as a therapeutic for celiac disease.

7 August 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JMJeremy Mills
Jeremy Mills
SKSagar D. Khare
Sagar D. Khare
JBJill M. Bolduc
Jill M. Bolduc
FFFarhad Forouhar
Farhad Forouhar
VMVikram Khipple Mulligan
Vikram Khipple Mulligan
DBDavid Baker
David Baker

25 June 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
CLChang C. Liu
Chang C. Liu
AMAntha V. Mack
Antha V. Mack
EBEric M. Brustad
Eric M. Brustad
JMJeremy Mills
Jeremy Mills
DGDan Groff
Dan Groff
PSPeter G. Schultz
Peter G. Schultz

12 September 2012 in ACS Synthetic Biology
Verified
Journal Article
Closed access
MHMatthew Harger
Matthew Harger
LZLei Zheng
Lei Zheng
AMAustin Moon
Austin Moon
CACasey Ager
Casey Ager
JAJu Hye An
Ju Hye An
JSJustin B. Siegel
Justin B. Siegel